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Introduction
Primary sinonasal mucosal melanoma (SNMM) is a rare
disease, occurring far less often than cutaneous lesions.
Melanomas arising from mucosal surfaces constitute
0.2–8.0% of all melanomas, and 55.4% of mucosal
melanomas are found in the head and neck.1–3 Studies
have estimated that SNMM comprises 3.5% of all malig-
nancies in the sinonasal region, 6.7% of head and neck
melanomas, and 1–2% of all malignant melanomas.4,5
In SNMM, tumors are usually diagnosed late in
their course and are therefore difficult to ablate. This
difficulty is likely to be compounded by the poor
response of the mucosal melanoma to radiotherapy,
with only a few successes reported.6,7 Surgical exci-
sion remains the treatment of choice for localized dis-
ease with or without regional lymph node metastases.
Chemotherapy is usually reserved for treatment fail-
ure or for treatment following development of distant
metastases.
Still, in the absence of well-studied cases and ran-
domized clinical trials, the appropriate treatment
modalities remain controversial. More information on
the incidence, progression, and treatment of SNMM
is required. The few studies of SNMM have focused
on patient populations in North America, primarily
on Caucasian and African-American populations. A few
studies have reported on Japanese patient populations,
but the incidence, progression and treatment of SNMM
in Asia is generally under-represented and not well
understood. This is significant as the disease may display
a racial discrepancy.
The present study is a retrospective review of the
medical records of 23 patients who were diagnosed
with primary SNMM and who were treated at Taipei
Veterans General Hospital between 1982 and 2002,
with the aim of furthering our understandings of the
incidence, progression and treatment of the disease.
To our knowledge, this is the first study to address
SNMM in a Chinese patient population.
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Methods
We performed a retrospective review of all cases of
mucosal melanoma diagnosed at Taipei Veterans Gen-
eral Hospital between 1982 and 2002. Morphologic
features of the melanomas, including histologic appear-
ance and melanin pigmentation, were assessed in tis-
sue sections following hematoxylin and eosin (H&E)
staining. Immunohistochemical staining for melanoma
markers (S-100 protein, HMB-45) were performed.
Metastatic lesions arising from cutaneous melanoma,
determined through direct physical examination and
surveys of patients’ medical histories, were excluded.
None of the patients had been previously diagnosed
with a malignant melanoma at any other site, or had a
subsequent diagnosis of primary cutaneous malignant
melanoma.
The following information was retrospectively col-
lected from medical charts: age, sex, site of lesion,
symptoms, duration of symptoms, treatment modali-
ties, failure pattern, and survival time. Regional lymph
node metastasis was identified by review of the pathol-
ogy, whereas distant metastasis was recorded according
to medical records and radiologic evidence.
Overall survival, disease-specific survival, and local
control rates were calculated using the Kaplan-Meier
method. Time was defined as the period from the first
treatment to the target event. Target events were death
(overall survival) and death due to SNMM (disease-
specific survival). Patients who died of other diseases
were censored for local control. If the tumor was never
eradicated, the local control period was 0. Those patients
who survived were followed until March 2005. Survival
regarding factors such as gender, primary sites, surgical
margins and clinical stages were analyzed by the log-
rank test.
As there is no provision within the TNM system
for staging SNMM, we employed the following arbi-
trary staging system: stage I was defined as primary
lesion, stage II as regional lymph node metastasis and
stage III as distant metastasis.
Results
Of the 294 cases of malignant melanoma diagnosed
at our institution during the study period, 47 (16.0%)
were from the mucous membrane. Of these, 23 were
from the sinonasal mucosa, whereas 8 were from the
oral cavity. Others were from the nasopharynx, eusta-
chian tube, vagina, rectum, anus, and stomach.
Twenty-three patients were retrospectively re-
cruited for the present study. Patient information is
presented in Table 1. Sixteen patients were male and
Table 1. Patient characteristics
Patient no. Age (yr) Sex Primary site Symptoms
1 65 M Ethmoid sinus Headache
2 57 M Nasal cavity Not applicable
3 71 M Nasal cavity Epistaxis, nasal obstruction, postnasal dripping
4 75 M Maxillary sinus Epistaxis, nasal obstruction, exophthalmus
5 39 M Nasal cavity Nasal obstruction
6 70 M Nasal cavity Nasal obstruction, purulent rhinorrhea, epistaxis
7 82 M Maxillary sinus Epistaxis, headache
8 69 F Maxillary sinus Purulent rhinorrhea, epistaxis
9 71 M Maxillary sinus Nasal obstruction
10 62 M Inferior turbinate Epistaxis, nasal obstruction
11 78 F Maxillary sinus Foul odor, epistaxis, nasal obstruction
12 70 M Inferior turbinate Epistaxis
13 80 F Maxillary sinus Epistaxis, nasal obstruction
14 59 M Maxillary sinus Epistaxis
15 71 M Nasal cavity Epistaxis
16 60 F Nasal cavity Epistaxis, nasal obstruction
17 71 M Nasal cavity Epistaxis, nasal obstruction
18 63 M Maxillary sinus Nasal obstruction
19 52 F Nasal cavity Epistaxis, nasal obstruction
20 57 F Nasal cavity Epistaxis
21 78 M Nasal cavity Epistaxis, nasal obstruction
22 81 F Middle turbinate Epistaxis, nasal obstruction
23 87 M Nasal cavity Epistaxis, nasal obstruction
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7 were female; their mean age was 68.2 years (range,
39–87 years).
The exact genesis site of SNMM was difficult to
ascertain. Tumors originated in paranasal sinuses in 
9 patients (the maxillary sinus in 8 and the ethmoid
sinus in 1), and in the nasal cavity in 7 (specifically,
the inferior turbinate in 2 patients and the middle
turbinate in 1). The most common presenting symp-
toms were epistaxis, noted in 18 patients, and nasal
obstruction, noted in 15. The initial visit to a physi-
cian ranged from 2 weeks to 1 year (mean, 3.1 months)
following the appearance of symptoms.
At the time of their initial visit, tumors were limited
to the local sinonasal region in 20 of the 23 patients.
Three patients displayed both local and distant lesions.
No patient had neck lymph node metastasis.
Treatment was varied. Surgery was the sole treat-
ment in 5 patients. In addition to surgery, adjuvant
radiation was performed in 12 patients, and adjuvant
chemotherapy in 1 patient. Two patients received radia-
tion only; 1 received chemotherapy only (dacarbazine
[DTIC] + tamoxifen). All 3 strategies were employed
for 2 patients.
Surgery included medial maxillectomy via the lat-
eral rhinotomy approach, the Caldwell-Luc operation,
and endoscopic excision. Postoperative radiotherapy
(mean dose, 5,422 cGy; range, 2,100–6,000 cGy) was
performed in 9 patients, excluding patient 10 who
did not receive the full course of radiotherapy because
of poor general condition. The radiation dose was
6,000 cGy for patient 7, who received radiotherapy
alone as the primary treatment.
Subsequent to diagnosis and treatment, except in
4 patients who died from other diseases, 19 patients
developed distant failures. Twelve had local and/or
regional recurrence with distant failures, and 7 had
isolated distant failures (Figure 1). The 5-year local
control rate was 52.3%. Mean interval to development
of local recurrence after initial treatment was 3.4 months
(range, 0.5–12 months), whereas the median interval to
distant metastasis — the time from the date of first treat-
ment to the date the distant metastasis was found —
was 12 months (Table 2). The lungs and liver were the
most frequent sites of dissemination (13 and 11 patients,
respectively), followed by bones (8 patients), adrenal
gland (4 patients), brain (2 patients), kidney (1 patient),
and pancreas (1 patient).
Follow-up was performed until March 2005. Sur-
vival ranged from 3–132 months. However, death due
to advanced disease was pronounced and occurred
rapidly within the first 24 months following initial treat-
ment. The 5-year overall survival rate was 15.65%, and
median overall survival time was 20 months; 5-year
disease-specific survival rate was 22.26%, and median
disease-specific survival time was 20 months (Figure 2).
The 5-year disease-free survival rate was 14.54%, and
median survival time was 20 months.
Mean 5-year overall survival time was 16 months for
males and 24 months for females. Statistically signi-
ficant differences in survival time were noted with
respect to both primary site and clinical stage (p < 0.05)
(Table 3). For primary site, mean 5-year overall sur-
vival time and disease-specific survival time were both
24 months for nasal cavity and 7 months for paranasal
sinus. For clinical stage, mean 5-year overall survival time
and disease-specific survival time were both 20 months
for stage I and 4 months for stage III.
Discussion
Primary SNMM occurs mainly in elderly people, and
equal gender distribution has been reported.8,9 In
addition, the disease may display a racial discrepancy.10
However, most of the reports of mucosal melanomas
in the English literature are based on patient popula-
tions in the United States and describe the occurrence
of mucosal melanomas in Caucasian and African-
American patients,3,4 and sometimes in Hispanic
American patients as well.2 A few reports describe the
occurrence in Japanese populations,11,12 but Asia as a
whole is under-represented in the English literature
with regard to mucosal melanomas.
There appears to be variable genetic predisposition
for mucosal melanoma in different races. Mucosal mel-
anomas constitute 1-quarter to 1-third of all melanomas
in Japanese patients, but < 2% of all melanomas in
Western patients.11,12 Melanomas in the sinonasal region
constitute 7–11% of all Japanese melanomas (at all sites),
0
7
7
0
2
3
0Local Regional
Distant
Figure 1. Patterns of treatment failure in patients with primary
sinonasal mucosal melanoma, excluding 4 patients who died from
other diseases. Nineteen patients developed distant failures, 12
had local and/or regional recurrence with distant failures, and 
7 had isolated distant failures.
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but < 1% of all Western melanomas.12,13 All of our
patients were Chinese in race. Of the cases treated at our
hospital between 1982 and 2002, 16% of lesions were
from mucous membranes, while 9% of all melanoma
cases were primary SNMM. Because of the lower inci-
dence of melanoma in Asians, and because of the lim-
ited number of studies, it is still difficult to ascertain
whether the incidence of mucosal melanoma actually
differs from that found in other Asian races.
Symptoms and signs are generally regarded as being
nonspecific. In the present study, epistaxis and nasal
obstruction were the major symptoms at presentation.
Most of the nasal lesions appeared as polypoid, fleshy,
and friable masses with black pigmentation, and thus
might have been regarded as nasal polyps.
Correct diagnosis of mucosal melanoma is not diffi-
cult when melanin-rich tumor cells can be identified on
histologic examination (such as H&E stain). However,
because amelanotic lesions may resemble many other
tumor cell types, including those of lymphoma, sarcoma,
poorly differentiated carcinoma, schwannoma and other
metastatic lesions of cutaneous melanomas,14–16 immu-
nohistochemical staining plays an important role in
diagnosis. S-100, HMB-45 and Melan-A are the most
Table 2. Treatment modalities and outcome
Patient no.
Duration of initial symptoms Initial Initial Metastatic
Outcome
Follow-up
before diagnosis (mo) stage treatment sites (mo)
1 I OP+RT Brain DOD 7
2 I OP Lung, liver, bone DOD 19
3 4 I OP+RT Liver, lumbar spine, ANED 132
adrenal gland,
kidney
4 0.5 I CT Lung, liver, bone DOD 16
5 12 I OP Lung, liver, bone, DOD 20
adrenal gland,
pancreas
6 3 I OP+RT Lung DOD 24
7 3 I RT Brain DOD 7
8 4 I OP+RT Retroperitoneum DOD 20
adrenal gland
9 2 I OP+RT+CT DOOC 10
10 1 I OP+RT Bone DOD 6
11 8 I OP+RT DOOC 3
12 3 III OP+RT Lung, liver, DOD 4
adrenal gland
13 1 III OP+RT Lung, liver DOD 3
14 4 I OP+RT+CT Liver DOD 20
15 2 I OP+RT Lung, liver DOD 45
16 1 I OP DOOC 65
17 3 I OP+RT Lung, liver, bone DOD 84
18 4 III OP+CT Lung DOD 5
19 3 I OP Lung, bone DOD 36
20 2 I OP+RT Lung, liver, bone DOD 24
21 3 I RT Lung, liver DOD 12
22 1 I OP+RT DOOC 28
23 6 I OP Lung DOD 25
OP = surgery; RT = radiotherapy; CT = chemotherapy; DOD = died of disease; ANED = alive with no evidence of disease; DOOC = dead of other cause.
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Figure 2. Five-year disease-free survival rate of 23 patients with
primary sinonasal melanoma.
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frequently employed stains. S-100 has a higher sensitiv-
ity than the others, while HMB-45 can be more specific
to melanoma cells. The highly specific Melan-A is used
when equivocal results are obtained with the traditional
immunohistochemical markers.17
Failure at the primary site is a frequent problem
for patients with SNMM. High recurrence rates may
be a result of multifocality or clinically unapparent,
diffuse, submucosal lymphatic spread of melanoma
cells. Therefore, even in the early clinical stage, localized
lesions may need to be treated with radical excision
without undue compromise of function.18 Regional
lymphatic metastasis is unusual in SNMM. A meta-
analysis of 550 patients with mucosal melanoma of the
head and neck documented such metastasis at initial
presentation in only 18.7% of cases, with only 16.4%
having regional metastasis following treatment.8 In
our study, no patient exhibited regional metastasis at
initial presentation and such metastasis was noted in
only 5 of 23 patients (21.7%) following treatment.
SNMM has a relatively high distant failure rate and,
unlike most cancers where the risk of death decreases
precipitously over time, can reappear at any time.19
Indeed, patients with SNMM are constantly at risk of
death due to the disease, and will ultimately die of it
because of a combination of local recurrence and
melanomatosis.20 Consistent with this bleak outlook,
the majority of patients reviewed in the present study
developed distant recurrence and could not be salvaged
because of advanced disease or involvement of vital
organs. There was a sole exception. Patient number 3
had liver, kidney, lumbar spine and bilateral adrenal
gland metastases after initial treatment. He received
salvage therapy 4 times (including surgery and radio-
therapy), and no residual lesion was noted during his
last follow-up 132 months after the initial treatment.
The reason for this patient’s resilience remains elusive,
but may be immune-related, with local surgical inter-
vention acting to decrease the tumor burden and main-
tain the indolent state of the immune system. Similarly,
Eneroth and Lundberg21 describe 2 cases of long-term
survival following repeated local and regional recur-
rences of a mucosal melanoma of the head and neck
upon salvage treatment, which serve to highlight the
value of repeated surgical procedures for recurrent dis-
eases, and a meticulous and lifelong follow-up.
Nonetheless, the rarity of SNMM makes it difficult
to determine the most appropriate treatment protocol.
Surgical resection of tumor masses offers the best way
for local control of mucosal melanoma, and is the
only means to achieve a disease-free period in these
patients.21,22 However, the overall prognosis is gener-
ally grave.23 In the present study, the mean 5-year
overall survival rate was only 15.65%.
The value of radiotherapy in the treatment of
SNMM is controversial. The use of postoperative radio-
therapy has not been shown to improve survival, likely
because of melanoma cells’ capacity to repair sublethal
damage, to the extent that it might be considered radio-
resistant to conventional fractionation schedules.24,25
Therefore, high-dose-per-fraction treatment is preferred
in the treatment of SNMM. Moreover, acute side effects
Table 3. Overall survival and disease-free survival in patients with primary sinonasal mucosal melanoma
Cases, n Median OS (mo) Median DSS (mo) Median DFS (mo) Median LCS (mo)
Gender
Male 16 16 19 7 24
Female 7 24 24 36
p 0.68 0.88 0.18 0.15
Primary site
Nasal cavity 14 24 24 25
Paranasal sinus 9 7 7 7
p 0.001 0.003 0.099 0.721
Surgical margin
Yes 8 20 20 5 20
No 11 36 36 36
p 0.093 0.093 0.097 0.258
Clinical stage
I 20 20 20 24
III 3 4 4 4 4
p < 0.001 < 0.001 0.001 0.256
OS = overall survival; DSS = disease-specific survival; DFS = disease-free survival; LCS = local control status.
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and long-term morbidity are less common in high-dose-
per-fraction than conventional treatment schedules.24
Chemotherapy as an adjuvant therapy has been
employed as well. However, results have been dis-
appointing. Immunotherapy in the form of bacillus
Calmette-Guérin vaccine, dendritic cell vaccine or cyto-
kines has been used as adjuvant therapy to treat iso-
lated cases of mucosal melanoma, but with limited
success.26,27 Gene therapy is another area of active
research.28,29 Since the majority of patients with SNMM
eventually die from distant metastasis, improvements
in overall survival will result from improvements in
systemic therapy.
Primary SNMM is a rare disease with poor progno-
sis and high rates of distant metastasis. Although the
majority of patients are initially seen with localized
lesions, most of the 23 patients in the current study
developed distant metastasis. Surgical resection offers
the best method for local control and is the only means
to achieve a disease-free period. Despite a variety of
treatments, the outcomes in the current study remained
dismal. Further studies of systemic therapy for mucosal
melanoma are required to improve the overall survival
rate for this disease.
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